ClinicalTrials.gg
RecruitingNCT07217873IV-KIDSUpdated Nov 26, 2025

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

A Phase 2/3 interventional study of Ferric carboxymaltose IV and Normal Saline (Placebo) in Scoliosis Correction, Iron Deficiency and Transfusion Blood, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 10 Years to 19 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Columbia University · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
10 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.

Planned enrollment
21st of 40
120 · median 134
Started
2025
with 1 other
Phase 2/3
Only one
of the 40
Registered
36th of 40
by date
Lead sponsor
1 of 40
Columbia University

Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one is the 21st largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 2/3, and was the 36th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 10 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing ferric carboxymaltose in Iron Deficiencies, or all of them as a file.
02

Study summary

Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. The proposed study is a randomized controlled trial of preoperative intravenous iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in this vulnerable population. Building evidence for patient blood management interventions such as iron supplementation is vital to ensuring high quality care of surgical patients and may reduce unnecessary transfusions amid recent blood shortages.

Read the detailed description

Adolescents undergoing spinal fusion surgery for scoliosis and/or kyphosis are poised to benefit from preoperative iron supplementation. Spinal fusion carries a risk of large surgical blood losses and perioperative red blood cell transfusion, which are associated with adverse outcomes in this population. These patients are mostly adolescent females, a group more susceptible to iron deficiency and resulting anemia at baseline due to iron losses with menses, and who suffer an additional insult to iron stores during surgery. Nevertheless, iron status is not routinely monitored in this setting and there is no standard of care for preoperative iron supplementation. Iron is a nutritionally essential trace element important not only for red blood cell production, but also for muscle function and neurotransmitter synthesis and signaling. Therefore, supplementation of poor iron status is an important target for optimizing hemoglobin prior to surgery, reducing transfusion rates and associated complications such as alloimmunization, and improving patient outcomes. On its own and as the primary cause of anemia, iron deficiency was identified as the only risk factor for transfusion which is modifiable preoperatively. In addition, iron supplementation is shown to alleviate impairments of physical and cognitive capacity associated with even mild forms of iron deficiency in adolescent and young adult females. A pilot study conducted at Columbia University Irving Medical Center identified iron deficiency in 36% of scoliosis patients prior to surgery, with preoperative iron status highly correlated with iron status during surgical recovery. Consequently, the investigators plan to examine iron deficiency as a modifiable risk factor for transfusion and impaired postoperative cognitive and physical capacity in this vulnerable population. Previous trials of brief iron interventions in high-risk adult surgical patients, mostly with unknown iron status, do not inform the care of adolescents and were not designed to address postoperative functional outcomes. The investigators will therefore perform a single-center randomized controlled trial in which adolescents with scoliosis and/or kyphosis identified using physiologically-based serum markers of poor iron status will be randomized to a one time preoperative dose of IV ferric carboxymaltose or placebo, to test the hypotheses that preoperative iron supplementation 1) reduces the rate of red blood cell transfusion, 2) improves postoperative neurocognition compared to a preoperative baseline, and 3) improves patient reported physical functioning during recovery. This study aims to improve outcomes in this vulnerable population and provide evidence for patient blood management approaches to reduce transfusions amid recent severe blood shortages.

03

Conditions studied

  • Scoliosis Correction
  • Iron Deficiency
  • Transfusion Blood
  • Surgery Complications
  • Spinal Fusion
  • Scoliosis Idiopathic Adolescent
  • Scoliosis Neuromuscular

Keywords

  • scoliosis
  • iron deficiency
  • blood transfusion
  • spinal fusion
  • iron supplementation
04

Who can participate

Ages eligible
10 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 10 -19 years old
  • diagnosis of scoliosis or kyphosis
  • scheduled for imminent spinal fusion procedure (\<6 weeks) at MS-CHONY
  • Iron deficiency or hypoferritinemia, defined as serum ferritin less than or equal to 50 μg/L

Exclusion criteria

Exclusion Criteria:

  • C-reactive protein > 10 mg/L
  • receiving nutritional support by report in the medical chart
  • self-reported history of reaction to iron-containing supplements
  • self-reported history of receiving intravenous iron supplements
  • self-reported history of iron overloaded state such as hereditary hemochromatosis or hemosiderosis
  • objection to receiving red blood cell transfusions
  • current pregnancy (identified by self-report or documentation of preoperative screening test in the medical record)
  • prisoners
  • patient or parent decides against study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intravenous ferric carboxymaltose

    Participants will receive ferric carboxymaltose, 15mg/kg up to 750mg intravenously, on the morning of surgery.

    Drug: Ferric carboxymaltose IV

  • Placebo comparator
    Intravenous normal saline

    Patients will receive normal saline, intravenously, on the morning of surgery.

    Drug: Normal Saline (Placebo)

  • No intervention
    Observational follow-up

    Participants who do not qualify for randomization may be invited to complete study measures through postoperative follow-up as part of an observational study.

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferric carboxymaltose is an intravenous treatment for iron deficiency.

  • DrugNormal Saline (Placebo)

    Normal saline is the recommended diluent for ferric carboxymaltose, and on its own serves as the placebo control for this study.

06

What researchers measure

Primary outcomes

  1. Incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion

    The patients that received a red blood cell transfusion either during procedure or postoperatively during their surgical hospitalization will be tallied.

    Time frame: 4-30 days

Secondary outcomes

  1. Percentage of Patients that experienced postoperative change in neurocognitive function

    The Cognitive Battery of the NIH Toolbox is a brief, valid, and reliable instrument designed to provide outcome measures in epidemiologic and longitudinal research that can be used for comparisons across a wide range of studies and populations. Individual measure scores in the battery reflect Executive Function, Attention, Verbal and Nonverbal Memory, Language, Processing Speed, and Working Memory, yielding a composite score. This composite is scored on a T-score, with 100 representing the mean normalized by age and education level, and a standard deviation of 10. A score of 100 indicates performance that was at the national average for the test-taking participant's age. Scores of 85 or lower indicate below average cognitive function. A decline of function is measured by comparing the mean change from baseline in the Cognitive Function Composite Scores in the study groups.

    Time frame: 2 to 3 months

  2. Percentage of patients that experienced postoperative change in self-reported physical capacity

    The PROMIS pediatric measures are a NIH Roadmap initiative to provide access to valid and reliable self-reported measures of health-related quality of life in children and adolescents. The PROMIS measures are scored on a T-score metric, where a score of 50 and standard deviation of 10 represents the average score for the general population in the United States. Higher PROMIS symptom scores indicate increased symptom burden, and higher PROMIS function scores indicate increased functioning. Decline would be identified through a mean change (decrease) from baseline in the Physical Functioning - Mobility scores; with secondary hypotheses for Physical Functioning - Upper Extremity, Physical Activity, and Fatigue.

    Time frame: 2 to 3 months

  3. Volume of perioperative RBC transfusion

    The volume that each patient receives either during procedure or postoperatively during surgical hospitalization will be summed and average calculated.

    Time frame: 4 to 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Qiu A, Fliginger D, Feit Y, Hassan F, Lenke LG, Li G, Hod EA, Eisler L. Estimating the prevalence of preoperative iron deficiency and its impact on red blood cell transfusion in adolescents undergoing scoliosis surgery: A pilot study. Transfusion. 2025 May;65(5):851-857. doi: 10.1111/trf.18246. Epub 2025 Apr 7. PubMed 40191932 ↗

Individual participant data

Plan to share: Undecided — We will make the determination to share or not share IPD at a later date.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Aug 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2025
First posted
Oct 20, 2025
StartActual
Nov 21, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07217873
Collaborators
Association for the Advancement of Blood & Biotherapies
Responsible party
Lisa Eisler (Assistant Professor of Anesthesiology, Columbia University) — Principal investigator
First posted
Oct 20, 2025
Start date
Nov 21, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 26, 2025

Study contacts

Lisa D Eisler, M.D.
Contact
ldl2113@cumc.columbia.edu
212-305-2413

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion